Precigen announces PRGN-2012 Phase 2 data expected Q2 2024; BLA submission planned H2 2024

PRECIGEN, INC.

PRGN-2012 Phase 2 pivotal data in RRP anticipated Q2 2024; BLA submission under accelerated approval H2 2024.
Commercial readiness preparations underway for potential PRGN-2012 launch in 2025.
PRGN-2009 Phase 2 study in OPSCC enrolling; cervical cancer trial to start Q1 2024.
PRGN-3006 Phase 1b dose expansion interim data expected H2 2024; Phase 1 showed 27% ORR in r/r AML.
New CD19 UltraCAR-T preclinical data presented; Phase 1 study preparation underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.